about
sameAs
Addition to inhaled corticosteroids of long-acting beta 2-agonists versus anti-leukotrienes for chronic asthmaAddition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma.Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthmaAdenosine receptors and asthma.Organic carbamates in drug design and medicinal chemistryTreatment heterogeneity in asthma: genetics of response to leukotriene modifiers.Zafirlukast inhibits complexation of Lsr2 with DNA and growth of Mycobacterium tuberculosisTherapeutic management of allergic diseases.Drug metabolism and pharmacokinetics.Gender and interindividual variability in pharmacokinetics.Pharmacokinetics in special populations.Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions.Cysteinyl-leukotriene receptor antagonism blunts the acute hypotensive response to endotoxin in cats.Characterization of enzymes responsible for biotransformation of the new antileukotrienic drug quinlukast in rat liver microsomes and in primary cultures of rat hepatocytes.Leukotriene Receptor Antagonists Inhibit Mitogenic Activity in Triple Negative Breast Cancer CellsType 2 NADH Dehydrogenase Is the Only Point of Entry for Electrons into the Streptococcus agalactiae Respiratory Chain and Is a Potential Drug Target.Fluconazole but not the CYP3A4 inhibitor, itraconazole, increases zafirlukast plasma concentrations
P2860
Q24200999-DBD4589D-B120-4555-A28D-D71557542C49Q24234499-F4DE2226-B022-4310-AD44-83185044C317Q24244152-42B715B0-366F-4513-86C4-AF847E6F6CB6Q24653697-D53C1B60-AFF4-4FA5-9B02-F784D288E0D9Q35365543-BE920CF4-2E31-46C2-8BE1-6033C427F796Q36775615-207F0D48-1AD6-4411-8874-E164A83EC66DQ36785897-D4FC3E5F-A465-4127-9B0F-1ED07DBFD4A8Q37550543-81810247-DB1F-4470-82E8-28BC62DA8D2EQ37550548-54CAE626-E2F4-4B10-9C5A-BB97CC2045BDQ37550556-E96EDEAD-933A-4434-9A7F-A3857EC7DB40Q37550561-110C3FA1-64A3-46BE-A7FB-E4A2E01B38AAQ38684505-616BD76E-D1E2-49E6-9F3E-C5F3EA0DDF3FQ42933777-41FE6C64-779F-4A33-9203-03BDEA10BEBBQ44789800-1DEA31AE-7603-4F61-83F5-2E185814C28CQ52723870-ABC95440-249C-4C8E-B9F9-CF067E00B913Q55518525-497C787B-7210-4C7E-970A-04D8AD7706F4Q57825115-6772A938-A0FF-4DE1-862A-41C201A389AE
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականին հրատարակուած գիտական յօդուած
@hyw
2002 թվականին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Pharmacokinetic profile of zafirlukast
@ast
Pharmacokinetic profile of zafirlukast
@en
Pharmacokinetic profile of zafirlukast
@nl
type
label
Pharmacokinetic profile of zafirlukast
@ast
Pharmacokinetic profile of zafirlukast
@en
Pharmacokinetic profile of zafirlukast
@nl
prefLabel
Pharmacokinetic profile of zafirlukast
@ast
Pharmacokinetic profile of zafirlukast
@en
Pharmacokinetic profile of zafirlukast
@nl
P1476
Pharmacokinetic profile of zafirlukast
@en
P2093
P N Richard Dekhuijzen
Peter P Koopmans
P304
P356
10.2165/00003088-200241020-00003
P407
P577
2002-01-01T00:00:00Z
P6179
1044779598